Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype
about
Screening for Anal Cancer in WomenEvolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008.Risk of second cancers in survivors of prolymphocytic leukemia: a SEER data analysis.The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer.Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care.Pooling prospective studies to investigate the etiology of second cancers.Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules.Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapyThe Importance of an In-depth Study of Immunoglobulin Gene Rearrangements When Ascertaining the Clonal Relationship between Concomitant Chronic Lymphocytic Leukemia and Multiple Myeloma.Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study.Second malignancies in patients with primary central nervous system lymphoma.Two smalls in one: Coincident small cell carcinoma and small lymphocytic lymphoma in a lymph node diagnosed by fine-needle aspiration biopsy.Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma: a Rochester Epidemiology Project population-based study in MinnesotaSurvival analysis in hematologic malignancies: recommendations for cliniciansRisk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma.Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis.Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemiaIncreased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based studyTherapy-related acute myeloid leukemia following treatment of lymphoid malignancies.The important role of radiation therapy in early-stage diffuse large B-cell lymphoma: time to review the evidence once again.Diffuse large B-cell lymphoma with concurrent gastric adenocarcinoma: case report and literature review.Radioimmunotherapy for B-cell non-hodgkin lymphomas.A protocol for prospective studies of 25-hydroxyvitamin D, leptin and body mass index in relation to cutaneous melanoma incidence and survivalRituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis.Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma.Differential diagnosis problems in a patient with dysphonia and chronic lymphocytic leukemiaIncidence of cutaneous squamous cell carcinoma in a New Zealand population of chronic lymphocytic leukaemia patients.Incidence and epidemiology of non-Hodgkin lymphoma and risk of second malignancy among 22 466 survivors in Israel with 30 years of follow-up.High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: ReDevelopment of second primary malignancy in patients with non-Hodgkin lymphoma: a nationwide population-based study.Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database.Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma.Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukemia - Still a Valid Treatment Option, or is the Game Over?Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma.Trends in excess mortality in follicular lymphoma at a population level.
P2860
Q28085226-2097E9EB-1472-4E81-B81C-3CC241D1E574Q30538788-221BB701-ACCD-42B1-80D4-815336999216Q31147302-2735A9E2-B7E2-44DD-BE02-58DD00E5CB1AQ33398044-BFC0AE35-4770-46B9-AA28-CC2E7D84C478Q33410060-4987C8CD-FA0E-43F2-8B5C-9D8D4B1D9AA4Q33581483-9F8386ED-24FF-4A29-8E8F-EBC328AF7793Q33992357-AD8A0605-55B5-4BD0-B0B1-BCA5AAA1D8FEQ34081881-3A16540C-6AA2-4B6C-8B2F-97C4C60C45D0Q34195072-889B6C8B-1246-44B6-A602-DCE8CF6C29CAQ34260518-1A890D77-85D9-480B-93D5-F1EB3D226EBBQ34549132-98960D63-33CE-4813-ABFE-3D2CEF62E3B0Q35262838-E1CE70EB-7B42-428F-956E-16392157EA85Q35788720-04F4CCEE-44AE-459B-AFAC-388CF5FFA8F1Q35838726-A56C97B5-6B10-40FA-BD66-2A0A4479A92DQ35867744-7333A897-CAEB-4A2C-BF7D-2B89978FA30DQ36036279-EB497DBD-8390-45FD-A6C4-C955409AF86AQ36090959-EC5B2B55-DDD0-4B3F-ADBB-1D02B3E421EFQ36822986-7F3B1B07-8DC3-48E5-B6B7-F263B4D8ACBFQ36929831-5AC5413F-1B54-44CD-BF7C-3ECB1D3F9450Q36935200-641F9575-32A8-450D-9F6A-F86C83860032Q37185719-B65BDD73-3D13-4C29-9B23-89F76D80A26CQ37699158-9AC8EAC4-B4FA-4F9F-9158-BB35D9B9EEADQ37934960-ADFBC91F-3676-4717-AE8B-59091A52B94BQ37961079-B4A07EFE-05BA-4A6E-B3D0-F32DE854DC8BQ38019790-633C909C-CD09-442B-BB16-0AA5FE04172BQ38373681-53F35548-FD96-44D5-AD2A-5E59C0E31381Q38673151-3F83C14A-5932-444F-AAC3-EADCA2CD687CQ38679176-68A42C26-5C96-46D1-A644-853649131784Q38881049-42121431-6F43-475A-94C9-5C07A775C644Q39260356-E61B31DF-2821-4C1B-B354-7D6E08331E11Q39354550-3502D7E4-4C65-43A7-9CF6-6FDD2178BB42Q39727079-91D8E7D4-B95B-4911-A25E-491E473E4837Q40063998-3A07A218-C22C-48E2-B323-F84D5D2ED6AAQ40375360-CA7EA0AF-7129-4DA3-88BA-83487BA9CA83Q40942679-6E21473A-9E6E-46B9-A0B7-4FC6F5877049Q41252640-0F1B3489-80A8-4174-9A28-068D96F6D360Q41496252-D864202E-90FD-43FB-8F67-BCC8765EC4A4Q41986069-CD359EBC-5F74-4C10-8286-6C6C51254EB4Q44676921-622A226E-BB17-4E2F-ACE1-DA441BC1DFF6Q48072671-E895E6D9-21F4-4F7D-87A7-368011BE5A5F
P2860
Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Second malignancy risks after ...... ifferences by lymphoma subtype
@ast
Second malignancy risks after ...... ifferences by lymphoma subtype
@en
Second malignancy risks after ...... ifferences by lymphoma subtype
@nl
type
label
Second malignancy risks after ...... ifferences by lymphoma subtype
@ast
Second malignancy risks after ...... ifferences by lymphoma subtype
@en
Second malignancy risks after ...... ifferences by lymphoma subtype
@nl
prefLabel
Second malignancy risks after ...... ifferences by lymphoma subtype
@ast
Second malignancy risks after ...... ifferences by lymphoma subtype
@en
Second malignancy risks after ...... ifferences by lymphoma subtype
@nl
P2093
P2860
P356
P1476
Second malignancy risks after ...... ifferences by lymphoma subtype
@en
P2093
Elizabeth C Bluhm
Joseph F Fraumeni
Lindsay M Morton
Lynn A G Ries
Margaret A Tucker
Martha S Linet
Neil Caporaso
Rochelle E Curtis
P2860
P304
P356
10.1200/JCO.2010.29.1112
P407
P577
2010-10-12T00:00:00Z